(IBB) Biotechnology - Overview
Etf: Biotech Stocks, Biotech Futures, Options, Swaps, Cash
Dividends
| Dividend Yield | 0.26% |
| Yield on Cost 5y | 0.23% |
| Yield CAGR 5y | 4.95% |
| Payout Consistency | 65.0% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | 2.46% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 10.46 |
| Character TTM | |
|---|---|
| Beta | 0.753 |
| Beta Downside | 0.635 |
| Drawdowns 3y | |
|---|---|
| Max DD | 24.85% |
| CAGR/Max DD | 0.41 |
Description: IBB Biotechnology January 09, 2026
The iShares Biotechnology ETF (IBB) commits at least 80% of its capital to the stocks that compose its benchmark index, while the remaining allocation may be used for futures, options, swaps, cash, or cash equivalents, making the fund non-diversified.
As of early 2026, IBB holds roughly $6.5 billion in assets, carries an expense ratio of 0.46%, and its top ten holdings include Amgen, Gilead Sciences, and Regeneron-companies that together account for about 35% of the portfolio. The biotech sector’s growth is heavily tied to FDA approval pipelines, R&D intensity (average R&D spend ≈ 20% of revenue for leading firms), and macro-drivers such as an aging global population and increasing healthcare spending.
For a deeper, data-driven look at IBB’s valuation and risk metrics, you might explore the analytical dashboards on ValueRay.
What is the price of IBB shares?
Over the past week, the price has changed by +1.48%, over one month by +2.18%, over three months by +10.57% and over the past year by +24.81%.
Is IBB a buy, sell or hold?
What are the forecasts/targets for the IBB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 182.4 | 4.2% |
IBB Fundamental Data Overview February 07, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 8.66b USD (8.66b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 8.66b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 8.66b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.69% (E(8.66b)/V(8.66b) * Re(8.69%) + (debt-free company))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)